罗素·优克福公司（Roussel Uclaf S.A.）是一家法国制药公司，赛诺菲制药企业的几家前身公司之一。
| Roussel-Uclaf S.A. | |
|---|---|
 巴黎第七区荣军院大道35号Roussel-Uclaf前总部 | |
| 公司类型 | 上市公司 (Société anonyme) |
| 公司结局 | 收购 |
| 后继机构 | 霍伊斯特公司 (Hoechst Marion Roussel) |
| 成立 |  法国巴黎 (1911年)Institut de Sérothérapie Hémopoïétique ISH (1920) Usines Chimiques des Laboratoires Français UCLAF (1928) Société Française de la Pénicilline SOFRAPEN (1947) (Roussel-Uclaf, S.A. incorporated 1961) |
| 结束 | September 30, 1997年[1] |
| 创办人 | Gaston Roussel |
| 代表人物 | Gaston Roussel (首席执行官, 1911–1947) Jean-Claude Roussel (首席执行官, 1961–1972) Jacques Machizaud (首席执行官, 1974–1981) Édouard Sakiz (首席执行官, 1981–1993) Ernst-Günter Afting (首席执行官, 1994–1995) Jean-Pierre Godard (首席执行官, 1995–1997) |
| 总部 | 巴黎 (1911–1995) 罗曼维尔, 法国 (1995–1997)[2] |
| 业务范围 | Worldwide |
| 产业 | Pharmaceutical |
| 产品 | Hemostyl (红血球生成素, horse serum) Rubiazol (百浪多息) Rythmodan (disopyramide) Decis (溴氰菊酯) Surgam (tiaprofenic acid) Claforan (头孢噻肟) Mifegyne (美服培酮, RU-486) Anandron (nilutamide) |
| 营业额 | ▲ 美元 3.01 billion (1996)[3] |
| 净利润 | ▲ 美元 340 million(1996)[3] |
| 员工人数 | 15,673 worldwide (1992)[4] 8,409 in France (1992)[4] 6,533 in France (1996)[5] |
历史
It was the second largest French pharmaceutical company[6] before it was acquired by 霍伊斯特公司 of 美因河畔法兰克福, 德国 in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States. Roussel Uclaf's agrochemical operations had been transferred to Hoechst Schering AgrEvo GmbH in 1994.
HMR subsequently merged in 1999 with Rhône-Poulenc to form Aventis, which then merged in 2004 with Sanofi-Synthélabo to form 赛诺菲, which was since renamed Sanofi. Hoechst Schering AgrEvo merged in 1999 with Rhône-Poulenc's agrochemical division to form Aventis CropScience, which was acquired by 拜耳 in 2002 and combined with Bayer's agrochemical division to form Bayer CropScience.
RU-486
In April 1980, as part of a formal research project at Roussel-Uclaf for the development of 糖皮质激素受体 受体拮抗剂s, chemist Georges Teutsch synthesized 美服培酮 (RU-38486, the 38,486th compound synthesized by Roussel-Uclaf from 1949 to 1980; shortened to RU-486); which was discovered to also be a 孕酮受体 antagonist.[7][8] In October 1981, endocrinologist Étienne-Émile Baulieu, a consultant to Roussel-Uclaf, arranged tests of its use for medical abortion in eleven women in 瑞士 by gynecologist Walter Herrmann at the 日内瓦大学's Cantonal Hospital, with successful results announced on April 19, 1982.[7][9] On October 9, 1987, following worldwide clinical trials in 20,000 women of mifepristone with a 前列腺素 analogue (initially 硫前列酮 or 吉美前列素, later 米索前列醇) for medical abortion, Roussel-Uclaf sought approval in France for their use for medical abortion, with approval announced on September 23, 1988.[7][10]
堕胎产品
1988年10月21日，为了回应反堕胎的抗议和大多数 (54.5%) 所有者HoechstAG的担忧，Roussel-Uclaf高管和董事会以16票对4票决定于1988年10月26日宣布停止米非司酮的分销[7][11]
两天后，法国政府下令Roussel-Uclaf重新分发米非司酮。[7][12]法国卫生部长Claude Évin 解释说：“我不能允许因堕胎争论剥夺妇女代表医学进步的产品。从政府批准该药物的那一刻起，RU-486立即已成为女性的财产，这不仅仅是一家制药公司的财产。”[7]1988年4月至1990年2月，仅法国已有34,000名妇女使用免费分发的米非司酮。
Mifegyne was subsequently approved in 大不列颠岛 on July 1, 1991,[13] and in 瑞典 in September 1992,[14] but until his retirement in late April 1994, Hoechst AG chairman Wolfgang Hilger, a devout 天主教会, blocked any further expansion in availability.[7][15] On May 16, 1994, Roussel-Uclaf announced that it was donating without remuneration all rights for medical uses of mifepristone in the U.S. to the Population Council,[16] which subsequently licensed mifepristone to Danco Laboratories, a new single-product company immune to antiabortion boycotts, which won 美国食品药品监督管理局 approval as Mifeprex on September 28, 2000.[17]
On April 8, 1997, after buying the remaining 43.5% of Roussel-Uclaf stock in early 1997,[18] Hoechst AG ($30 billion annual revenue) announced the end of its manufacture and sale of Mifegyne ($3.44 million annual revenue) and the transfer of all rights for medical uses of mifepristone outside of the U.S. to Exelgyn S.A., a new single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz.[19] In 1999, Exelgyn won approval of Mifegyne in 11 additional countries, and in 28 more countries over the following decade.[20]
参考
Wikiwand in your browser!
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.
